Movement Disorders

The FDA has approved the investigational new drug application for AV-101 for the treatment of dyskinesia in patients with Parkinson disease who are treated with levodopa.

Join NeurologyLive and the Women Neurologists Group on Twitter to celebrate women in neurology on National Women Physicians Day.

The Infinity DBS system is the only directional DBS system approved to target all major areas associated with movement disorders, including Parkinson disease and essential tremor.

The phase 2 clinical trial of CAD-1883 will assess the efficacy and safety of the drug compared to placebo.

Neurology News Network for the week ending January 27, 2020.

Findings from the small-scale study showed that the drug had target engagement with β-glucocerebrosidase as well as cerebrospinal fluid penetration.

Findings from a large scale analysis show higher rates of cognitive impairment and neuropsychiatric disturbances in patients with parkinsonism-dominant motor-manifest individuals.

Use of rimabotulinumtoxinB (Myobloc; US WorldMeds) result in statistically significant reductions in sialorrhea compared to placebo with both 2500 U and 3500 U doses.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 17, 2020.

The neurostimulation device may help to accelerate the removal of a patient’s breathing tube by restoring neurological swallowing control.

Neurology News Network for the week ending January 11, 2020.

Neurology News Network for the week ending January 4, 2020.

Recent findings suggest that patients with Parkinson disease may have impaired swimming ability, even in light of motor improvements with treatment.